MPM BioImpact’s Trevi Therapeutics TRVI Stock Holding History

MPM BioImpact’s Portfolio TRVI Stock Details TRVI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$57.3M	Sell	3,073,577 -224,853	-7%	-$3.27M	3.5%	9
2026 Q1	$39.4M	Buy	3,298,430 +11,343	+0.3%	+$127K	3.04%	10
2025 Q4	$41.2M	Sell	3,287,087 -119,868	-4%	-$1.39M	4.71%	4
2025 Q3	$31.2M	Hold	3,406,955	–	–	5.1%	4
2025 Q2	$18.6M	Sell	3,406,955 -21,411	-0.6%	-$133K	3.23%	9
2025 Q1	$21.6M	Buy	3,428,366 +333,470	+11%	+$1.59M	3.71%	8
2024 Q4	$12.8M	Buy	3,094,896 +1,556,379	+101%	+$4.98M	1.81%	25
2024 Q3	$5.14M	Buy	1,538,517 +28,343	+2%	+$84.3K	0.77%	34
2024 Q2	$4.5M	Buy	1,510,174 +169,214	+13%	+$470K	0.7%	42
2024 Q1	$4.63M	Buy	+1,340,960	New	+$2.99M	0.74%	36

Other funds holding TRVI

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

MPM BioImpact's TRVI Position: Q2 2026 in Review

MPM BioImpact reduced its Trevi Therapeutics (TRVI) stake by 6.8% in Q2 2026, selling an estimated $3.27M and leaving 3,073,577 shares worth $57.3M. The position accounts for 3.5% of the portfolio, ranked #9.

MPM BioImpact first reported a position in TRVI in Q1 2024 and has held it in 10 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

MPM BioImpact held 3,073,577 shares of Trevi Therapeutics worth $57.3M as of Q2 2026.
MPM BioImpact sold 224,853 Trevi Therapeutics shares in Q2 2026, an estimated $3.27M.
Trevi Therapeutics made up 3.5% of MPM BioImpact's portfolio in Q2 2026, its #9 holding.
MPM BioImpact first reported a position in Trevi Therapeutics in Q1 2024 and has held it in 10 quarters since.
218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on MPM BioImpact's 13F filing for Q2 2026, filed 14 Aug 2026.